Symbotic Inc (SYM) Stock Price Today
Aura AI Summary
Key Stats
- $5.04BMarket Cap
- 1,572,729Volume
- IndustrialsSector
- $87.3052W High
- $37.9052W Low
- 25 DaysTypical Hold Time
- $3.29BEnterprise Value
- -Div Yield
- -Trading Activity
Track Symbotic Inc (SYM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Symbotic Inc has traded between a low of $37.9 and a high of $87.3, highlighting its annual price range. Buy and sell Symbotic Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Most Recent News
Berkshire Hathaway earned $479M dividends from $1.3B American Express stake last year.
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026
JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.
Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.